6,41 $
0,47 % heute
Nasdaq, 6. Oktober, 17:48 Uhr
ISIN
US48576U1060
Symbol
KPTI
Berichte

Karyopharm Therapeutics, Inc. Aktie News

Neutral
PRNewsWire
5 Tage alt
NEWTON, Mass. , Oct. 1, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 333 restricted stock units (RSUs) to one newly-hired employee.
Neutral
PRNewsWire
26 Tage alt
– Top-Line Results Anticipated in March 2026 – NEWTON, Mass. , Sept. 10, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has completed enrollment in the Phase 3 SENTRY trial, which is evaluating selinexor in combination with ruxolitinib in JAKi-naïve myelofibrosis patients.
Neutral
PRNewsWire
etwa ein Monat alt
NEWTON, Mass. , Sept. 2, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 466 restricted stock units (RSUs) to two newly-hired employees.
Neutral
Seeking Alpha
etwa 2 Monate alt
Karyopharm Therapeutics Inc. (NASDAQ:KPTI ) Q2 2025 Earnings Call August 11, 2025 8:00 AM ET Company Participants Brendan Twohig Strong - Corporate Participant SVP of Investor Relations & Corporate Communications - Corporate Participant Lori A. Macomber - EVP, CFO & Treasurer Reshma Rangwala - Executive VP, Chief Medical Officer & Head of Research Richard A.
Neutral
PRNewsWire
etwa 2 Monate alt
– New Patient Screening for Phase 3 SENTRY Trial in Myelofibrosis Expected to Close This Week; Top-Line Results Anticipated in March 2026 – – Total Revenue was $37.9 Million; U.S. XPOVIO® (selinexor) Net Product Revenue was $29.7 Million, up 6% compared to Second Quarter of 2024 – – Reaffirms Full-Year 2025 Total Revenue Guidance of $140 Million to $155 Million; Updates U.S. XPOVIO Net Product ...
Neutral
PRNewsWire
2 Monate alt
-- Conference Call Scheduled for Monday, August 11, 2025, at 8:00 a.m. ET -- NEWTON, Mass.
Neutral
PRNewsWire
2 Monate alt
NEWTON, Mass. , Aug. 1, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 333 restricted stock units (RSUs) to one newly-hired employee.
Neutral
PRNewsWire
3 Monate alt
NEWTON, Mass. , July 1, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 666 restricted stock units (RSUs) to two newly-hired employees.

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen